Why This Patent News Is Big For Bristols Acquisition Of Celgene | Latest News RSS feed

Why This Patent News Is Big For Bristols Acquisition Of Celgene - Latest News

Why This Patent News Is Big For Bristol's Acquisition Of Celgene

Celgene stock jumped Monday after U.S. officials declined to move forward with a patent challenge from a rival for its cancer drug Revlimid, an analyst said. "We believe investors have remained concer... read more

The big life sciences patent developments in January

The success of Bristol ... why Bristol-Myers’ purchase of Celgene could turn out to be a damp squib if Dr Reddy’s wins a suit relating to follow-on patents that cover flagship cancer treatment Revlimi... read more

3 Reasons Bristol-Myers' $90 Billion Mega-Merger Makes It A Must Own Stock

Then Bristol would appeal which means that the earliest generic rivals could hit the market is 2021, just one year earlier than the patent expirations. What about the big ... This is why Bristol and C... read more

Looking for another news?

Bristol-Myers Squibb's Q4 Earnings Update Shows Why It Needs Celgene

Here are three reasons why ... Celgene acquisition? The bad news about pulling the sBLA filing underscored just how much of BMS' fortunes ride on Opdivo. Buying Celgene provides more product diversifi... read more

Cure for an Ailing Industry? Pharma Multinationals Seek a Panacea in Indian Acquisitions

“Sanofi-Aventis Scans India for Acquisitions ... And that is why Shantha was so important.” The company is still on the takeover trail. “There will be more shopping on the horizon,” Viehbacher told Bl... read more

How to invest in a scary economy

That's what this story will help you do -- by tackling in sober-minded (as opposed to politically-spun) fashion the big ... faces major patent expirations next year. But Bristol-Myers has sold off anc... read more

'The tide is coming in': Wall Street is becoming increasingly convinced one of the stock market's most important sectors is headed for disaster

But he said it's still bad news for ... are possible acquisition targets, as Celgene was when Bristol-Myers Squibb agreed to buy it in one of the largest health care deals ever. That also helps those ... read more

In a Huge Biopharma Shakeup, Bristol-Myers to Buy Celgene For $74B

traded at just $66 before the merger news broke this morning. The Bristol acquisition is “a best-case scenario that should be immediately utilized by Celgene shareholders,” wrote Porges. It “dilutes i... read more

BMS Reports Q4: Analysis Of Its Stock And Of Celgene

7 for patent information). I last focused on BMY in August 2017, with an article titled Bristol ... Celgene. Some perspective: my first CELG article was published on June 19, 2014, titled Why ... read more

Bristol-Myers Squibb and Celgene

So our big biopharma news this morning is Bristol-Myers Squibb buying Celgene, for $74 billion ... This will produce a rather large oncology portfolio, which is surely why BMS has suddenly decided to ... read more

Pfizer Reportedly Rules Out Bristol-Myers Squibb Deal -- Here Are 3 Better Acquisition Targets

Pfizer chairman and CEO Ian Read told Citi analyst Andrew Baum recently that an acquisition of Bristol-Myers Squibb (BMS) is off the table for now, according to financial news ... why Pfizer would be ... read more

Here's The Dark Horse Contender That Could Break Up Bristol-Celgene

... for Bristol in the wake of its planned Celgene acquisition puts it at a discount to Amgen. This "creates a potential window to do a deal," Syed said. The deal would be accretive if it uses Bristol ... read more

FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us